

PE/Cyanine7 anti-mouse/human CD11b Antibody

Catalog# / Size	101215 / 25 µg 101216 / 100 µg
Clone	M1/70
Regulatory Status	RUO
Other Names	αM integrin, Mac-1, Mo1, CR3, Ly-40, C3biR, ITGAM
Isotype	Rat IgG2b, κ
Description	CD11b is a 170 kD glycoprotein also known as αM integrin, Mac-1 α subunit, Mol, CR3, and Ly-40. CD11b is a member of the integrin family, primarily expressed on granulocytes, monocytes/macrophages, dendritic cells, NK cells, and subsets of T and B cells. CD11b non-covalently associates with CD18 (β2 integrin) to form Mac-1. Mac-1 plays an important role in cell-cell interaction by binding its ligands ICAM-1 (CD54), ICAM-2 (CD102), ICAM-4 (CD242), iC3b, and fibrinogen.

Product Details

Verified Reactivity	Mouse, Human, Cynomolgus, Rhesus
Reported Reactivity	Chimpanzee, Baboon, Rabbit
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	C57BL/10 splenocytes
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration	0.2 mg/ml
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 10 ⁶ cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser	Blue Laser (488 nm) Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes	Clone M1/70 has been verified for immunocytochemistry (ICC) and frozen immunohistochemistry (IHC-F). Additional reported applications (for relevant formats of this clone) include: immunoprecipitation ^{1,4} , <i>in vitro</i> blocking ^{3,9,12} , depletion ^{2,8} , immunofluorescence microscopy ^{6,7,10} , immunohistochemistry of acetone-fixed frozen sections ^{5,11-13} , and spatial biology (IBEX) ^{35,36} . For <i>in vivo</i> studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) (Cat. No. 101248).
Additional Product Notes	BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.
Application References	1. Springer T, <i>et al.</i> 1978. <i>Eur. J. Immunol.</i> 8:539. (IP) 2. Ault K and Springer T. 1981. <i>J. Immunol.</i> 126:359. (Deplete)
(PubMed link indicates	

BioLegend citation)

3. Springer TA, *et al.* 1982. *Immunol. Rev.* 68:171. (Block)
4. Ho MK and Springer TA. 1983. *J. Biol. Chem.* 258:2766. (IP)
5. Flotte TJ, *et al.* 1983. *Am. J. Pathol.* 111:112. (IHC)
6. Noel GJ, *et al.* 1990. *J. Clin. Invest.* 85:208. (IF)
7. Allen LA and Aderem A. 1996. *J. Exp. Med.* 184:627 (IF)
8. D'Amico A and Wu L. 2003. *J. Exp. Med.* 198:293. (Deplete)
9. Brickson SJ, *et al.* 2003. *Appl Physiol.* 95:969. (Block)
10. Clatworthy MR and Smith KG. 2004. *J. Exp. Med.* 199:717. (IF)
11. Hata H, *et al.* 2004. *J. Clin. Invest.* 114:582. (IHC)
12. Zhang Y, *et al.* 2002. *J. Immunol.* 168:3088. (IHC)
13. Iwasaki A and Kelsall BL. 2001. *J. Immunol.* 166:4884 (IHC, FC)
14. Tailleux L. 2003. *J. Exp. Med.* 197:121. (Block, FC)
15. Olver S, *et al.* 2006. *Cancer Research* 66:571. (FC)
16. Tan SL, *et al.* 2006. *J. Immunol.* 176:2872. (FC) [PubMed](#)
17. Ponomarev ED, *et al.* 2006. *J. Immunol.* 176:1402. (FC)
18. Dzhagalov I, *et al.* 2007. *Blood* 109:1620. (FC)
19. Fazilleau N, *et al.* 2007. *Nature Immunol.* 8:753.
20. Rasmussen JW, *et al.* 2006. *Infect. Immun.* 74:6590. [PubMed](#)
21. Napimoga MH, *et al.* 2008. *J. Immunol.* 180:609. [PubMed](#)
22. Elqaraz-Carmon V, *et al.* 2008. *J. Lipid. Res.* 49:1894. [PubMed](#)
23. Kim DD, *et al.* 2008. *Blood* 112:1109. [PubMed](#)
24. Guo Y, *et al.* 2008. *Blood* 112:480. [PubMed](#)
25. Norian LA, *et al.* 2009. *Cancer Res.* 69:3086. (FC) [PubMed](#)
26. Baumgartner CK, *et al.* 2010. *J. Immunol.* 184:573. [PubMed](#)
27. Charles N, *et al.* 2010. *Nat. Med.* 16:701. (FC) [PubMed](#)
28. Whiteland J, *et al.* 1995. *J. Histochem. Cytochem.* 43:313. (IHC)
29. Weber GF, *et al.* 2014. *J Exp Med.* 211:1243. [PubMed](#)
30. Ashok A, *et al.* 2015. *Toxicol Sci.* 143:64. [PubMed](#)
31. Price PJ, *et al.* 2015. *J Immunol.* 194:1164. [PubMed](#)
32. Doni A, *et al.* 2015. *J Exp Med.* 212:905. [PubMed](#)
33. Ferreira R, *et al.* 2016. *J Infect Dis.* 213: 669 - 673. [PubMed](#)
34. Peterson VM, *et al.* 2017. *Nat. Biotechnol.* 35:936. (PG)
35. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
36. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

Product Citations

1. Parsons M, *et al.* 2014. *J Immunol.* 192:1361. [PubMed](#)
2. Tebartz C, *et al.* 2015. *J Immunol.* 194:1100. [PubMed](#)
3. Quispe Calla N, *et al.* 2016. *Sci Rep.* 6:37723. [PubMed](#)
4. D'Alessandro G, *et al.* 2020. *Eur J Immunol.* 50:705. [PubMed](#)
5. DeSouza-Vieira T, *et al.* 2020. *Cell Rep.* 33:108317. [PubMed](#)
6. Gogoi H, *et al.* 2020. *Front Immunol.* 11:620833333. [PubMed](#)
7. Liu K, *et al.* 2021. *Cell Metabolism.* 33(3):666-675.e4. [PubMed](#)
8. Hatzl K, *et al.* 2019. *Nat Immunol.* 20:86. [PubMed](#)
9. Tran NT, *et al.* 2019. *Cell Rep.* 28:3510. [PubMed](#)
10. Lin C *et al.* 2019. *Immunity.* 50(1):137-151. [PubMed](#)
11. Okunuki Y, *et al.* 2018. *Proc Natl Acad Sci U S A.* 115:E6264. [PubMed](#)
12. Yu X, *et al.* 2020. *Nat Commun.* 11:1110. [PubMed](#)
13. Wang L, *et al.* 2021. *J Nanobiotechnology.* 19:56. [PubMed](#)
14. Kuo PC, *et al.* 2021. *Brain Commun.* 3:fcab187. [PubMed](#)
15. Cheresh P, *et al.* 2021. *Int J Mol Sci.* 22:.. [PubMed](#)
16. Deng R, *et al.* 2022. *Adv Sci (Weinh).* 9:e2103343. [PubMed](#)
17. Odom CV, *et al.* 2021. *J Immunol.* 207:1891. [PubMed](#)
18. Correa S, *et al.* 2020. *ACS Nano.* 2224:14. [PubMed](#)
19. Kim JS, *et al.* 2020. *Immunity.* 54(1):176-190.e7. [PubMed](#)
20. Gazit R, *et al.* 2014. *J Exp Med.* 211:1315. [PubMed](#)
21. Giorgetti E, *et al.* 2020. *Cell Reports.* 29(6):1539-1554.e7. [PubMed](#)
22. Thelin MA, *et al.* 2017. *Diabetes.* 66:2220. [PubMed](#)
23. Zhang LJ, *et al.* 2019. *Immunity.* 50:121. [PubMed](#)
24. Abels ER *et al.* 2019. *Cell Rep.* 28(12):3105-3119. [PubMed](#)
25. Frisbee AL, *et al.* 2019. *Nat Commun.* 10:2712. [PubMed](#)
26. Groza D, *et al.* 2018. *Oncoimmunology.* 7:e1424676. [PubMed](#)
27. Alissafi T, *et al.* 2018. *J Clin Invest.* 128:3840. [PubMed](#)
28. Iwamoto H *et al.* 2018. *Cell metabolism.* 28(1):104-117. [PubMed](#)
29. McGill BE *et al.* 2018. *The Journal of Neuroscience.* 38(1):200-219. [PubMed](#)
30. Kitagawa S, *et al.* 2022. *NPJ Vaccines.* 7:115. [PubMed](#)
31. Rodrigues M, *et al.* 2022. *Biochem J.* 479:1891. [PubMed](#)
32. Jung MY, *et al.* 2022. *Neurooncol Adv.* 4:vdac017. [PubMed](#)
33. Schönberger K, *et al.* 2022. *Cell Stem Cell.* 29:131. [PubMed](#)
34. Di Martile M, *et al.* 2020. *J Immunother Cancer.* 8:.. [PubMed](#)
35. Sharma GP, *et al.* 2021. *PLoS One.* 16:e0259042. [PubMed](#)
36. Li Z, *et al.* 2021. *Immunology.* 163:105. [PubMed](#)
37. Radovanovic I, *et al.* 2014. *J Immunol.* 193:1290. [PubMed](#)
38. Zaslona Z, *et al.* 2014. *J Immunol.* 193:4245. [PubMed](#)
39. Zheng W, *et al.* 2021. *Wellcome Open Research.* 6:52. [PubMed](#)
40. Mogilenko DA, *et al.* 2020. *Immunity.* 54(1):99-115.e12. [PubMed](#)
41. Riether C, *et al.* 2021. *Cell Reports.* 34(4):108663. [PubMed](#)
42. Yu K, *et al.* 2021. *Cell Reports.* 35(12):109273. [PubMed](#)
43. Kurelac I, *et al.* 2019. *Nat Commun.* 10:903. [PubMed](#)

44. Kobayashi Y, *et al.* 2018. PLoS One. 13:e0195008. [PubMed](#)
45. Delás MJ, *et al.* 2019. Cell Rep. 27:719. [PubMed](#)
46. Wei H, *et al.* 2021. Malar J. 20:89. [PubMed](#)
47. Van Den Eeckhout B, *et al.* 2020. NPJ Vaccines. 5:64. [PubMed](#)
48. Hickey A, *et al.* 2021. Front Microbiol. 12:653587. [PubMed](#)
49. Morgan PK, *et al.* 2021. J Biol Chem. 297:101341. [PubMed](#)
50. Yang C, *et al.* 2021. J Immunother Cancer. 9:. [PubMed](#)
51. Piepke M, *et al.* 2021. J Neuroinflammation. 18:265. [PubMed](#)
52. Jiang W, *et al.* 2021. Oncol Lett. 22:625. [PubMed](#)
53. Chen T, *et al.* 2021. JCI Insight. 6:. [PubMed](#)
54. Shen H, *et al.* 2015. Infect Immun . 83: 2694 - 2704. [PubMed](#)
55. Periasamy S, *et al.* 2017. Nat Commun. 8:15564. [PubMed](#)
56. Saggi G, *et al.* 2018. Nat Commun. 9:5058. [PubMed](#)
57. Yuzhu Hou *et al.* 2018. Immunity. 49(3):490-503 . [PubMed](#)
58. Bowers E, *et al.* 2018. Nat Med. 24:95. [PubMed](#)
59. Yang X, *et al.* 2020. Blood Sci. 2:89. [PubMed](#)
60. Deslyper G, *et al.* 2021. Parasitology. 148:539. [PubMed](#)
61. Martin R, *et al.* 2014. J Leukoc Biol. 96:151. [PubMed](#)
62. Shemer A, *et al.* 2020. Immunity. 53(5):1033-1049.e7. [PubMed](#)
63. Yamamoto K, *et al.* 2021. Cell Reports. 36(8):109576. [PubMed](#)
64. Uroda T, *et al.* 2020. Nat Protoc. 15:2107. [PubMed](#)
65. Akhmetzyanova ER, *et al.* 2019. Front Cell Neurosci. 12:507. [PubMed](#)
66. Lubkin A *et al.* 2019. Cell host & microbe. 25(3):463-470 . [PubMed](#)
67. Gibson EM, *et al.* 2019. Cell. 176:43:00. [PubMed](#)
68. Juttukonda LJ, *et al.* 2017. Cell Host Microbe. 22:531. [PubMed](#)
69. LaFleur MW, *et al.* 2019. Nat Immunol. 20:1335. [PubMed](#)
70. Somerville TD, *et al.* 2020. eLife. 9:e53381. [PubMed](#)
71. Go DM, *et al.* 2021. Cell Mol Gastroenterol Hepatol. 12:715. [PubMed](#)
72. Park JA, *et al.* 2021. J Hematol Oncol. 14:142. [PubMed](#)
73. Zong L, *et al.* 2021. NPJ Aging Mech Dis. 7:25. [PubMed](#)
74. Almutairi F, *et al.* 2021. Front Immunol. 12:772288. [PubMed](#)
75. Enriquez AB, *et al.* 2022. iScience. 25:104305. [PubMed](#)
76. Royzman D, *et al.* 2022. Front Immunol. 13:1012647. [PubMed](#)
77. Ellis G, *et al.* 2015. EMBO Rep. 16: 1203-1218. [PubMed](#)
78. Vazquez S, *et al.* 2015. Exp Hematol. 43: 578-585. [PubMed](#)
79. Shade K, *et al.* 2015. J Exp Med. 212:457. [PubMed](#)
80. Sasaki K, *et al.* 2019. Nat Commun. 10:3878. [PubMed](#)
81. Angelidis I, *et al.* 2019. Nat Commun. 10:963. [PubMed](#)
82. Xu X, *et al.* 2021. J Nanobiotechnology. 19:376. [PubMed](#)
83. Walker FC, *et al.* 2021. PLoS Pathog. 17:e1009402. [PubMed](#)
84. Johansen AZ, *et al.* 2022. Pharmaceuticals. 14:. [PubMed](#)
85. Liu Y, *et al.* 2022. Nat Commun. 13:2665. [PubMed](#)
86. Beauchamp EM, *et al.* 2021. Blood Cancer Discov. 6:. [PubMed](#)
87. Dodagatta-Marri E, *et al.* 2021. Cell Rep. 36:109309. [PubMed](#)
88. Super M, *et al.* 2021. Nat Biomed Eng. Online ahead of print. [PubMed](#)
89. Kulkarni NN, *et al.* 2021. J Biol Chem. 297:100828. [PubMed](#)
90. Jia X, *et al.* 2021. Front Cell Dev Biol. 9:685522. [PubMed](#)
91. Klopfenstein N, *et al.* 2021. PLoS Pathog. 17:e1009387. [PubMed](#)
92. Koh F, *et al.* 2015. Proc Natl Acad Sci U S A. 112:1734. [PubMed](#)
93. Kohn M, *et al.* 2021. Front Immunol. 580594:12. [PubMed](#)
94. Vasilijevic J, *et al.* 2017. PLoS Pathog. 13:e1006650. [PubMed](#)
95. Meeks K, *et al.* 2009. J Immunol. 183:8026. [PubMed](#)
96. Liang Z, *et al.* 2020. Pain. 161:2089. [PubMed](#)
97. Hore ZL, *et al.* 2021. Wellcome Open Res. 6:68. [PubMed](#)
98. Wang L, *et al.* 2021. Cancer Immunol Res. 9:348. [PubMed](#)
99. Enriquez AB, *et al.* 2022. iScience. 25:104305. [PubMed](#)
100. Shin JE, *et al.* 2021. Heliyon. 7:e08433. [PubMed](#)
101. Aegerter H, *et al.* 2020. Nat Immunol. 0.975694444. [PubMed](#)
102. Zhang S, *et al.* 2020. Front Immunol. 1.757638889. [PubMed](#)
103. Kirschbaum K, *et al.* 2016. Proc Natl Acad Sci U S A. 113: 13227 - 13232. [PubMed](#)
104. Varol D *et al.* 2017. Immunity. 46(6):1030-1044 . [PubMed](#)
105. Snell LM, *et al.* 2018. Immunity. 49:678. [PubMed](#)
106. Amo-Aparicio J, *et al.* 2021. Theranostics. 11:9805. [PubMed](#)
107. Mansouri S, *et al.* 2021. J Immunol. 206:2233. [PubMed](#)
108. Goldman E, *et al.* 2021. Cells. 10:. [PubMed](#)
109. Dokoshi T, *et al.* 2021. J Clin Invest. 131:. [PubMed](#)
110. Pan YC, *et al.* 2021. Mol Ther Oncolytics. 20:175. [PubMed](#)
111. Xie Z, *et al.* 2020. Light Sci Appl. 0.486805556. [PubMed](#)
112. Gomzikova MO, *et al.* 2020. Sci Rep. 10:10740. [PubMed](#)
113. He Y, *et al.* 2021. Cell Metabolism. 33(5):988-1000.e7. [PubMed](#)
114. Okubo K, *et al.* 2021. Cell Reports. 35(7):109142. [PubMed](#)
115. Gozgit JM, *et al.* 2021. Cancer Cell. .: [PubMed](#)
116. Kooreman NG *et al.* 2018. Cell stem cell. 22(4):501-513 . [PubMed](#)
117. Proto JD *et al.* 2018. Immunity. 49(4):666-677 . [PubMed](#)
118. Secondini C, *et al.* 2017. Oncoimmunology. 6:e1316437. [PubMed](#)
119. Huang YL, *et al.* 2021. Commun Biol. 4:229. [PubMed](#)
120. Littwitz-Salomon E, *et al.* 2021. Nat Commun. 12:5376. [PubMed](#)
121. Synn CB, *et al.* 2022. Clin Transl Immunology. 11:e1364. [PubMed](#)
122. Jia Q, *et al.* 2021. Theranostics. 4699:11. [PubMed](#)
123. Dobosz E, *et al.* 2021. Dis Model Mech. :14. [PubMed](#)

124. Mulas F, *et al.* 2020. Cell Mol Immunol. . [PubMed](#)
125. Zhu H, *et al.* 2021. Cell Metabolism. .: [PubMed](#)
126. Bambouskova M, *et al.* 2021. Cell Reports. 34(10):108756. [PubMed](#)
127. Ringel AE, *et al.* 2020. Cell. 183(7):1848-1866.e26. [PubMed](#)
128. Pérez-Girón J, *et al.* 2015. J Vis Exp. 100: 52803. [PubMed](#)
129. Suresh MV, *et al.* 2019. JCI Insight. 4:e133103. [PubMed](#)
130. Patel S, *et al.* 2019. Viruses. 0.877083333. [PubMed](#)
131. Bradley KC, *et al.* 2019. Cell Rep. 28:245. [PubMed](#)
132. Kumar MP, *et al.* 2018. Cell Rep. 25:1458. [PubMed](#)
133. Steuerman Y *et al.* 2018. Cell systems. 6(6):679-691 . [PubMed](#)
134. , *et al.* 2021. Eur J Immunol. 51:2708. [PubMed](#)
135. Uddin MJ, *et al.* 2022. Mucosal Immunol. 15:165. [PubMed](#)
136. Wang D, *et al.* 2021. Nat Commun. 12:2674. [PubMed](#)
137. Boulay A, *et al.* 2015. J Neurosci. 35:4427. [PubMed](#)
138. Trefzer A, *et al.* 2021. Cell Reports. 34(6):108748. [PubMed](#)
139. Lim CX, *et al.* 2020. Cell Rep. 3793:30. [PubMed](#)
140. Li Z, *et al.* 2018. Front Immunol. 9:347. [PubMed](#)
141. Marcus A *et al.* 2018. Immunity. 49(4):754-763 . [PubMed](#)
142. Van Winkle JA *et al.* 2018. Cell host & microbe. 24(5):665-676 . [PubMed](#)
143. LaFleur MW, *et al.* 2019. Nat Commun. 10:1668. [PubMed](#)
144. Wilson DH, *et al.* 2020. Nat Commun. 0.767361111. [PubMed](#)
145. Tran NT, *et al.* 2020. STAR Protocols. 1(1):100028. [PubMed](#)
146. Endoh M, *et al.* 2020. Cell Reports. 30(6):1823-1834. [PubMed](#)
147. Li H, *et al.* 2020. Nature. 584:274. [PubMed](#)
148. Sibilio A, *et al.* 2022. iScience. 25:103790. [PubMed](#)
149. Dey S, *et al.* 2020. J Immunother Cancer. 8:. [PubMed](#)
150. Shen M, *et al.* 2022. Nat Cancer. 3:60. [PubMed](#)
151. Liu H, *et al.* 2022. Front Pharmacol. 13:949316. [PubMed](#)
152. Frenis K, *et al.* 2021. Basic Res Cardiol. 31:116. [PubMed](#)
153. Crouse B, *et al.* 2020. NPJ Vaccines. 0.277083333. [PubMed](#)
154. Lee L, *et al.* 2016. PLoS One. 11:e0167693. [PubMed](#)
155. Arce-Cerezo A, *et al.* 2015. Sci Rep. 5: 1448. [PubMed](#)
156. Ballet R, *et al.* 2014. PLoS Pathog. 10:1004550. [PubMed](#)
157. Choi EW, *et al.* 2020. Sci Rep. 10:12001. [PubMed](#)
158. Denny JE, *et al.* 2019. Sci Rep. 2.786111111. [PubMed](#)
159. Liu C *et al.* 2019. Immunity. 51(2):381-397 . [PubMed](#)
160. Simula L *et al.* 2018. Cell reports. 25(11):3059-3073 . [PubMed](#)
161. Gao C, *et al.* 2017. Mol Neurobiol.. 10.1007/s12035-016-0318-0. [PubMed](#)
162. Khare P, *et al.* 2017. J Autoimmun. 10.1016/j.jaut.2017.09.002. [PubMed](#)
163. Monaghan KL, *et al.* 2020. J Vis Exp. . [PubMed](#)
164. Scholz F, *et al.* 2015. J Immunol. 195: 2335-2342. [PubMed](#)
165. Koelwyn GJ, *et al.* 2020. Nat Med. 1452:26. [PubMed](#)
166. Kim SJ, *et al.* 2020. Cell Mol Immunol. 17:728. [PubMed](#)
167. Robinett RA *et al.* 2018. Cell systems. 7(1):41-48 . [PubMed](#)
168. Nowlan B, *et al.* 2019. Haematologica. 105:71. [PubMed](#)
169. Mohamed E, *et al.* 2020. Immunity. 52(4):668-682.e7.. [PubMed](#)
170. Wuggenig P, *et al.* 2020. Commun Biol. 3:130. [PubMed](#)
171. Merrell AJ, *et al.* 2021. Hepatology. 74:444. [PubMed](#)
172. Chen C, *et al.* 2021. J Virol. 95:e0082921. [PubMed](#)
173. Yu W, *et al.* 2022. Nat Commun. 13:3544. [PubMed](#)
174. Nahrendorf W, *et al.* 2021. eLife. 10:00. [PubMed](#)
175. Mansouri S, *et al.* 2020. Mucosal Immunol. 0.954861111. [PubMed](#)
176. Sasaki Y, *et al.* 2015. PLoS One. 10: 0131176. [PubMed](#)
177. Kalafati L, *et al.* 2020. Cell. 183:771. [PubMed](#)
178. Burgener SS, *et al.* 2019. Cell Rep. 27:3646. [PubMed](#)
179. Duarte D, *et al.* 2018. Cell Stem Cell. 22:64. [PubMed](#)
180. Zhang CR, *et al.* 2022. Blood Cancer Discov. 3:220. [PubMed](#)
181. Takaku S, *et al.* 2022. Evid Based Complement Alternat Med. 2022:6122955. [PubMed](#)
182. Wang S, *et al.* 2021. Commun Biol. 22:. [PubMed](#)
183. Wang W, *et al.* 2021. J Am Heart Assoc. 10:e019142. [PubMed](#)
184. Song J, *et al.* 2021. Am J Physiol Heart Circ Physiol. 320:H323. [PubMed](#)
185. Bent EH, *et al.* 2021. Nat Commun. 12:6218. [PubMed](#)
186. Calderon B, *et al.* 2015. J Exp Med. 212: 1497-1512. [PubMed](#)
187. Richardson ET, *et al.* 2015. PLoS One. 10: 1371. [PubMed](#)
188. Moro T, *et al.* 2016. PLoS One. 11: 0146592. [PubMed](#)
189. Kobia FM, *et al.* 2020. PLoS Biol. 18:e3000850. [PubMed](#)
190. Bordas M, *et al.* 2020. Int J Mol Sci. 21:00. [PubMed](#)
191. Bellomo A, *et al.* 2020. Immunity. 53(1):127-142.e7. [PubMed](#)
192. Jiang L, *et al.* 2020. Cell. 183(5):1219-1233.e18. [PubMed](#)
193. Onai N, *et al.* 2020. Int J Mol Sci. :22. [PubMed](#)
194. Celik H, *et al.* 2018. Cancer Cell. 34:741. [PubMed](#)
195. Alexander Mildner *et al.* 2017. Immunity. 46(5):849-862 . [PubMed](#)
196. Yousef H, *et al.* 2019. Nat Med. 25:988. [PubMed](#)
197. Ivan DC, *et al.* 2021. Front Immunol. 12:666961. [PubMed](#)
198. Franklin DA, *et al.* 2020. JCI Insight. 5:. [PubMed](#)
199. Omatsu Y, *et al.* 2022. Nat Commun. 13:2654. [PubMed](#)
200. Schönberger K, *et al.* 2022. STAR Protoc. 3:101408. [PubMed](#)
201. Njock MS, *et al.* 2022. J Extracell Vesicles. 11:e12228. [PubMed](#)
202. Bagati A, *et al.* 2020. Cancer Cell. 39(1):54-67.e9. [PubMed](#)
203. Gicheva N, *et al.* 2016. Biochem Biophys Res Commun. 479:1-4. [PubMed](#)

204. Beauchamp N, *et al.* 2010. J Virol. 84:10191. [PubMed](#)
205. Wang Y, *et al.* 2020. eLife. 9:e57438. [PubMed](#)
206. Yu L, *et al.* 2020. Nat Commun. 2.045833333. [PubMed](#)
207. McKenzie MD, *et al.* 2019. Cell Stem Cell. 25:258. [PubMed](#)
208. Clemente-Casares X, *et al.* 2017. Immunity. 47:974. [PubMed](#)
209. Contreras NA, *et al.* 2019. PLoS Pathog. 15:e1007890. [PubMed](#)
210. Cantor DJ *et al.* 2019. Cell reports. 26(1):108-118 . [PubMed](#)
211. Baratin M, *et al.* 2017. Immunity. 47:349. [PubMed](#)
212. Coley WD *et al.* 2018. F1000Research. 2018 Mar 14 [revised 2018 Jan 1] 0.5125. [PubMed](#)
213. Zhao N, *et al.* 2018. J Clin Invest. 26:84. [PubMed](#)
214. Sun L, *et al.* 2022. Adv Sci (Weinh). 9:e2104051. [PubMed](#)
215. Canedo T, *et al.* 2021. Neuropsychopharmacology. 46:2358. [PubMed](#)
216. Johnson RM, *et al.* 2021. Front Immunol. 11:614697. [PubMed](#)
217. Kiss M, *et al.* 2020. Cancer Immunol Res. 9:309. [PubMed](#)
218. Gourvest M, *et al.* 2021. Leukemia. . [PubMed](#)
219. McPhee C, *et al.* 2013. J Immunol. 191:4581. [PubMed](#)
220. Fujimura N, *et al.* 2016. Sci Rep. 5:11664. [PubMed](#)
221. Tsunekuni K, *et al.* 2020. J Clin Med. 9:00. [PubMed](#)
222. Huang WC, *et al.* 2020. Adv Mater. 32:e2005637. [PubMed](#)
223. Shin M, *et al.* 2020. Cell Chem Biol. 314:27. [PubMed](#)
224. Kaiser S, *et al.* 2020. Glia. 2427:68. [PubMed](#)
225. Aggio-Bruce R, *et al.* 2020. Mol Neurobiol. . [PubMed](#)
226. Santopaolo M, *et al.* 2021. Front Immunol. 609406:12. [PubMed](#)
227. Asada S, *et al.* 2018. Nat Commun. 9:2733. [PubMed](#)
228. Kong XF, *et al.* 2018. Nat Immunol. 19:973. [PubMed](#)
229. Rosen DA, *et al.* 2019. Sci Transl Med. 11:eaau5266. [PubMed](#)
230. Dokoshi T, *et al.* 2020. Cell Rep. 30:61. [PubMed](#)
231. Van Den Eeckhout B, *et al.* 2020. NPJ Vaccines. 0.252777778. [PubMed](#)
232. Süß P, *et al.* 2020. Cell Reports. 30(12):4082-4095. [PubMed](#)
233. Molgora M, *et al.* 2020. Cell. 182:886. [PubMed](#)
234. Shi J, *et al.* 2022. Front Pharmacol. 12:818326. [PubMed](#)
235. Gao P, *et al.* 2020. Front Immunol. 1.636111111. [PubMed](#)
236. Chen S, *et al.* 2015. Cancer Res . 7: 519-531. [PubMed](#)
237. Groppa E, *et al.* 2015. EMBO Mol Med. 2015; 7: 1366 - 1384. [PubMed](#)
238. Gharib S, *et al.* 2014. J Leukoc Biol. 95:9. [PubMed](#)
239. Alfaro M, *et al.* 2008. Proc Natl Acad Sci U S A. 105:18366. [PubMed](#)
240. Walker JA, *et al.* 2020. Immunity. 51(1):104-118. [PubMed](#)
241. Winter C, *et al.* 2018. Cell Metab. 28:175. [PubMed](#)
242. Tippimanchai DD, *et al.* 2018. Oncoimmunology. 7:e1438105. [PubMed](#)
243. Liu G, *et al.* 2022. Theranostics. 12:2248. [PubMed](#)
244. Fan HH, *et al.* 2021. Methods Mol Biol. 2276:203. [PubMed](#)
245. Monteiro LB, *et al.* 2020. MethodsX 7:100938. [PubMed](#)
246. Rodriguez-Tirado C, *et al.* 2022. Cancers (Basel). 14:. [PubMed](#)
247. Lau P, *et al.* 2022. Cell Mol Immunol. . [PubMed](#)
248. Harding CL, *et al.* 2020. Front Cell Infect Microbiol. 10:328. [PubMed](#)
249. Chavez JS, *et al.* 2022. Cells. 11:. [PubMed](#)
250. Boulch M, *et al.* 2021. Sci Immunol. 6:. [PubMed](#)
251. Xu G, *et al.* 2015. Free Radic Biol Med. 87: 15-25. [PubMed](#)
252. Zhang S, *et al.* 2016. PLoS Pathog. 12: 1005617. [PubMed](#)
253. Saul S, *et al.* 2019. J Leukoc Biol. N/A. [PubMed](#)
254. Severe N *et al.* 2019. Cell Stem Cell. 25(4):570-583 . [PubMed](#)
255. Boguslawski KM, *et al.* 2020. Sci Adv. 6:eaax7515. [PubMed](#)
256. Wang L, *et al.* 2020. J Nanobiotechnology. 18:38. [PubMed](#)
257. Akhand SS, *et al.* 2020. Cancer Immunol Res. 8:1542. [PubMed](#)
258. Mansouri S, *et al.* 2021. J Immunol. 206:2233. [PubMed](#)
259. Franklin R, *et al.* 2022. Nat Commun. 13:2350. [PubMed](#)
260. Gawish R, *et al.* 2022. Elife. 11:. [PubMed](#)
261. Zhang B, *et al.* 2021. Front Neurol. 607370:12. [PubMed](#)
262. Young K, *et al.* 2021. Cell Stem Cell. . [PubMed](#)
263. Lucas ED, *et al.* 2020. Cell Reports. 33(2):108258. [PubMed](#)
264. Zysset D, *et al.* 2016. Nat Commun. 7:13151. [PubMed](#)
265. Huang J, *et al.* 2013. J Immunol Methods. 387:254. [PubMed](#)
266. Maas SLN, *et al.* 2020. J Neuroinflammation. 17:120. [PubMed](#)
267. Qi S, *et al.* 2020. Theranostics. 10:1814. [PubMed](#)
268. Zheng W, *et al.* 2019. Cell Rep. 29:1747. [PubMed](#)
269. Lalor R, *et al.* 2019. Nutrients. 11. [PubMed](#)
270. Cai T, *et al.* 2022. Front Immunol. 13:1009932. [PubMed](#)
271. Scheyltjens I, *et al.* 2022. Nat Protoc. 17:2354. [PubMed](#)
272. Zhang Y, *et al.* 2022. J Immunother Cancer. 10:. [PubMed](#)
273. Wang Y, *et al.* 2022. Nat Cell Biol. 24:230. [PubMed](#)
274. Song X, *et al.* 2022. Transl Oncol. 15:101306. [PubMed](#)
275. Xie Z, *et al.* 2020. Light Sci Appl. 9:161. [PubMed](#)

RRID

AB_312798 (BioLegend Cat. No. 101215)

AB_312799 (BioLegend Cat. No. 101216)

Antigen Details

Structure	Integrin family, associates with integrin β_2 (CD18), 170 kD
Distribution	Granulocytes, monocytes/macrophages, dendritic cells, NK cells, subsets of T and B cells
Function	Adhesion, chemotaxis
Ligand/Receptor	ICAM-1 (CD54), ICAM-2 (CD102), ICAM-4 (CD242), iC3b, fibrinogen
Cell Type	B cells, Dendritic cells, Granulocytes, Macrophages, Monocytes, Neutrophils, NK cells, T cells, Tregs
Biology Area	Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity, Neuroscience, Neuroscience Cell Markers
Molecular Family	Adhesion Molecules, CD Molecules
Antigen References	1. Barclay A, <i>et al.</i> 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Springer TA. 1994. <i>Cell</i> 76:301. 3. Coxon A, <i>et al.</i> 1996. <i>Immunity</i> 5:653.
Gene ID	16409 3684


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

APC anti-mouse/human CD11b, Biotin anti-mouse/human CD11b, FITC anti-mouse/human CD11b, PE anti-mouse/human CD11b, PE/Cyanine5 anti-mouse/human CD11b, Purified anti-mouse/human CD11b, PE/Cyanine7 anti-mouse/human CD11b, Alexa Fluor® 488 anti-mouse/human CD11b, Alexa Fluor® 647 anti-mouse/human CD11b, Alexa Fluor® 700 anti-mouse/human CD11b, Pacific Blue™ anti-mouse/human CD11b, APC/Cyanine7 anti-mouse/human CD11b, PerCP/Cyanine5.5 anti-mouse/human CD11b, PerCP anti-mouse/human CD11b, Brilliant Violet 421™ anti-mouse/human CD11b, Brilliant Violet 570™ anti-mouse/human CD11b, Brilliant Violet 605™ anti-mouse/human CD11b, Brilliant Violet 650™ anti-mouse/human CD11b, Brilliant Violet 711™ anti-mouse/human CD11b, Brilliant Violet 785™ anti-mouse/human CD11b, Brilliant Violet 510™ anti-mouse/human CD11b, Ultra-LEAF™ Purified anti-mouse/human CD11b, Purified anti-mouse/human CD11b (Maxpar® Ready), Alexa Fluor® 594 anti-mouse/human CD11b, PE/Dazzle™ 594 anti-mouse/human CD11b, APC/Fire™ 750 anti-mouse/human CD11b, TotalSeq™-A0014 anti-mouse/human CD11b, Brilliant Violet 750™ anti-mouse/human CD11b, TotalSeq™-B0014 anti-mouse/human CD11b, TotalSeq™-C0014 anti-mouse/human CD11b, Spark NIR™ 685 anti-mouse/human CD11b, PE/Fire™ 640 anti-mouse/human CD11b, Spark YG™ 593 anti-mouse/human CD11b, Spark YG™ 570 anti-mouse/human CD11b, PE/Fire™ 810 anti-mouse/human CD11b, APC/Fire™ 810 anti-mouse/human CD11b Antibody, Spark Blue™ 550 anti-mouse/human CD11b, Spark UV™ 387 anti-mouse/human CD11b

Product Data



C57BL/6 mouse bone marrow cells were stained with CD11b (clone M1/70) PE/Cyanine7 (filled histogram) or rat IgG2b, κ PE/Cyanine7 isotype control (open histogram) (gated on total cells).

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally

similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587